Old Web
English
Sign In
Acemap
>
authorDetail
>
Yusang Jiang
Yusang Jiang
Janssen Pharmaceutica
Medicine
Internal medicine
Psoriatic arthritis
Guselkumab
Adverse effect
3
Papers
23
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
2021
RMD Open
Christopher T. Ritchlin
Philip S. Helliwell
Wolf-Henning Boehncke
Enrique R. Soriano
Elizabeth C. Hsia
Alexa P. Kollmeier
Soumya D. Chakravarty
Federico Zazzetti
Ramanand A Subramanian
Xie L. Xu
Qing C Zuraw
S. Sheng
Yusang Jiang
Prasheen Agarwal
B. Zhou
Yanli Zhuang
M. Shawi
Chetan Karyekar
Atul Deodhar
Show All
Source
Cite
Save
Citations (4)
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through 1 Year in Biologic-naïve Psoriatic Arthritis Patients.
2020
Arthritis & Rheumatism
Iain B. McInnes
Proton Rahman
Alice B. Gottlieb
Elizabeth C. Hsia
A. Kollmeier
Soumya D. Chakravarty
Xie L. Xu
Ramanand A Subramanian
Prasheen Agarwal
S. Sheng
Yusang Jiang
B. Zhou
Yanli Zhuang
Désirée van
der Heijde
Philip J. Mease
Show All
Source
Cite
Save
Citations (7)
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
2018
Annals of the Rheumatic Diseases
Peter C. Taylor
Michael Schiff
Qingmin Wang
Yusang Jiang
Yanli Zhuang
Regina Kurrasch
Shruti Daga
Ravi Rao
Paul P. Tak
Benjamin Hsu
Show All
Source
Cite
Save
Citations (12)
1